PR97499

MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire=KYODO JBN/ --

-- Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to

treat eye conditions, will advise company's development of ocular tissue

rejuvenation therapeutics

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA

medicines to cure untreatable, age-related conditions, today announced that

Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic

products as an advisor to the company.

Photo -

https://mma.prnewswire.com/media/1882156/Albert_Wu_Turn_Biotechnologies.jpg

A board-certified ophthalmologist and fellowship-trained specialist in

oculoplastic and orbital surgery, Wu's academic work has focused on developing

treatments for vision loss and eye disease.

At Turn Bio, he will shepherd work on TRN-004, a formulation to rejuvenate

ocular tissues, including corneal, limbal and conjunctival epithelial cells, as

well as corneal endothelial cells. Preclinical results show the formulation

reduces inflammation, oxidative stress, and cell senescence.

TRN-004 is a tailored protein cocktail to rejuvenate targeted cells in the eye.

It is produced using Turn Bio's unique mRNA-based ERA™ (Epigenetic

Reprogramming of Aging) platform.

"Albert's life mission is to transform ophthalmology by making regenerative

medicine an accepted treatment for people worldwide suffering from diseases of

the eye," said Anja Krammer, the company's CEO. "His vision and experience will

help us redefine how eye doctors treat age-related vision conditions for which

no real cure exists."

Wu has nearly two decades of experience with ophthalmology and cellular

biology. He has been honored by the National Institutes of Health, American

Society of Ophthalmic Plastic and Reconstructive Surgery, Icahn School of

Medicine at Mount Sinai, the University of Washington and Yale University.

"Our work has the potential to revolutionize eye care to preserve patients'

vision and, ultimately, restore it," said Wu. "The ability to produce cell

rejuvenation therapies and deliver them with pinpoint accuracy offers enormous

promise to millions of people around the world whose sight has been compromised

by untreatable conditions."

Wu received his bachelor's degree in Molecular Biophysics and Biochemistry from

Yale University, his medical degree and doctoral degree in Molecular and

Cellular Biology from the University of Washington. He has co-authored 55

articles on his research discoveries and has contributed to textbooks on

ophthalmology and ophthalmologic oncology. He is a frequent presenter at

national and international medical conferences.

ABOUT TURN BIOTECHNOLOGIES

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the

cellular level. The company's proprietary mRNA platform technology, ERA™,

restores optimal gene expression by combatting the effects of aging in the

epigenome. This restores the cells' ability to prevent or treat disease, heal

or regenerate tissue and fight incurable chronic diseases.

The company is currently completing pre-clinical research on tailored therapies

targeting indications in dermatology and immunology, as well as developing

therapies for ophthalmology, osteo-arthritis and the muscular system. For more

information, see www.turn.bio .

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup

jim@rightstorygroup.com or (312) 543-9026

SOURCE Turn Biotechnologies, Inc.